Precigen Inc. (PGEN) will be presenting data from phase II portion of its pivotal phase I/II study of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis at the ASCO Annual Meeting today.
PRGN-2012 is an investigational off-the-shelf AdenoVerse gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus (HPV) 6 or HPV 11 for the treatment of recurrent respiratory papillomatosis (RRP).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com